Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Metasyn

This article was originally published in The Gray Sheet

Executive Summary

Metasyn: Contrast imaging agent manufacturer completes $5.1 mil. financing, from which proceeds will support "ongoing development of our lead vascular agent, MS-325, including the U.S. clinical trials expected to begin in the second half of 1996," the company says. New investors Advent International and Fidelity Ventures joined existing Metasyn investors Accel Partners and Bessemer Venture Partners in the financing. Cambridge, Massachusetts-based Metasyn's MS-325 agent is intended to be used with magnetic resonance imaging systems to produce diagnostic images of blood vessels. Imaging with MS-325 "has the potential to replace a large portion of invasive, catheter- based x-ray angiograms used today," Metasyn says...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts